Aplastic anemia is bone marrow-borne disease. Aplastic anemia occurs when the bone marrow responsible for the production of red blood cells (red blood cells), white blood cells (white blood cells) and clot cells (platelets) is unable to produce enough.
Although there are no problems in the blood cells produced by the bone marrow, it does not meet the needs of the body in terms of number. This disease, which has mild to severe stages and varieties, can lead to life problems.
Stomach Cell Treatment of Plasma Anemide SVF
The SVF stem cell is a complex stem cell population used in the treatment of autoimmune diseases, which contains many different stem cells and produces a synergistic effect. The stem cells (especially mesenchymal stem cells) in the SVF act as immunomodulators, repairing and reprogramming the cells of the immune system.
Causes of Plasma Anemia
Bone marrow is responsible for producing many of the cells in our body. The platelet immune system sees healthy blood stem cells as a foreign cell and tries to destroy it. This results in a decrease in blood cells and therefore a number of serious problems. Therefore, aplasic anemia is generally regarded as an immune system disease. It has also been shown that this disease may be inherited. However, it has been stated that the following aplastic anemia may cause the following situations.
- Exposure to harmful chemicals such as gasoline, arsenic and pesticides.
- High dose radiation and chemotherapy used in cancer treatment.
- Treatment methods used in diseases such as rheumatoid arthritis.
- Rarely, pregnancy period, sometimes anaplastic anemia can be exacerbated after birth.
- Plasma anemia may occur in cancerous cases that begin in another region but have gone on to the bone marrow.
- Abuljadayel IS, Mohanty D, Suri RK. A novel autologous stem cell procedure for the treatment of aplastic anaemia using reprogrammed mature adult cells: a pilot study. The Indian Journal of Medical Research. 2012;135(6):853-872.
- Starý J. et al. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplantation. 2005;13: 15-16.
- Neal S. Young, et al. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108: 2509-2519.
* Initiation of stem cell therapy is primarily a physician assessment and subsequent patient decision. DOKU BIOTECHNOLOGY is not a treatment practitioner. These results refer to the findings obtained as a result of scientific and clinical studies.